THE DIABETES CENTRE FINANCIAL STATEMENTS FOR THE YEAR ENDED JUNE 30, 2017

Deloitte.

Deloitte Yousuf Adil

Chartered Accountants #18-B/1 Chohan Mansion, G-8 Markaz, Islamabad Pakistan

Tel: +92 (51) 8350601 +92 (51) 8734400 Fax: +92 (51) 8350602

www.deloitte.com

AUDITORS' REPORT TO THE MEMBERS

We have audited the annexed balance sheet of **The Diabetes Centre** (the Company) as at June 30, 2017 and the related income and expenditure account, cash flow statement and statement of changes in funds together with the notes forming part thereof, for the year then ended and we state that we have obtained all the information and explanations which, to the best of our knowledge and belief, were necessary for the purposes of our audit.

It is the responsibility of the Company's management to establish and maintain a system of internal control, and prepare and present the above said statements in conformity with the approved accounting standards and the requirements of the Companies Ordinance, 1984. Our responsibility is to express an opinion on these statements based on our audit.

We conducted our audit in accordance with the auditing standards as applicable in Pakistan. These standards require that we plan and perform the audit to obtain reasonable assurance about whether the above said statements are free of any material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the above said statements. An audit also includes assessing the accounting policies and significant estimates made by management, as well as, evaluating the overall presentation of the above said statements. We believe that our audit provides a reasonable basis for our opinion and after due verification, we report that:

- a) in our opinion, proper books of accounts have been kept by the Company as required by the Companies Ordinance, 1984;
- b) in our opinion:
 - i) the balance sheet and income and expenditure account together with the notes thereon have been drawn up in conformity with the Companies Ordinance, 1984, and are in agreement with the books of account and are further in accordance with accounting policies consistently applied;
 - ii) the expenditure incurred during the year was for the purpose of the Company's business; and
 - the business conducted, investments made and the expenditure incurred during the year were in accordance with the objects of the Company;
- c) in our opinion and to the best of our information and according to the explanations given to us, the balance sheet, income and expenditure account, cash flow statement and the statement of changes in funds together with the notes forming part thereof conform with approved accounting standards as applicable in Pakistan, and, give the information required by the Companies Ordinance, 1984 in the manner so required, and respectively give a true and fair view of the state of the Company's affairs as at June 30, 2017 and of the surplus, its cash flows and changes in funds for the year then ended; and

Deloitte.

Deloitte Yousuf Adil Chartered Accountants

d) in our opinion, no Zakat was deductible at source under the Zakat and Ushr Ordinance, 1980 (XVIII of 1980).

Deloitte Yousuf Adil Chartered Accountants

Engagement Partner: Rana M. Usman Khan

Islamabad Date: March 10, 2018

THE DIABETES CENTRE BALANCE SHEET AS AT JUNE 30, 2017

		2017	2016
	Note -	(Rup	ees)
ASSETS			
Non-current assets			
Property and equipment	4 [219,914,822	160,610,81
ntangible assets	5	298,904	564,94
Security deposit		200,000	200,00
		220,413,726	161,375,75
Current assets			
Stock	6 Г	1,857,670	2,102,59
Prepayments, accrued interest and other receivables	7	541,335	143,33
nvestment	8	20,000,000	20,000,00
Cash and bank balances	9	50,101,002	17,715,26
		72,500,007	39,961,18
TOTAL ASSETS		292,913,733	201,336,93
Less: Liabilities			
Trade and other payables	10	1,382,665	951,35
NET ASSETS		291,531,068	200,385,58
Funds			
Accumulated surplus fund	Г	263,785,201	190,574,94
Restricted fund - Zakat		21,620,867	9,810,64
		285,406,068	200,385,58
Surplus on revaluation of land	4 _	6,125,000	
		291,531,068	200,385,58
Contingencies and commitments	11		
The annexed notes from 1 to 22 form an integral part of these financial	al statements.		

CHIEF EXECUTIVE OFFICER

Infr

THE DIABETES CENTRE INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED JUNE 30, 2017

General Fund	Restricted Fund	Total	Total
<u> </u>			Total
INCOME Note	Rupe	es	
INCOME.			
Clinical income 12 22,487,989	-	22,487,989	12,609,908
Donations 13 62,450,008	50,491,684	112,941,692	85,331,915
Other income 14 1,186,557	-	1,186,557	1,152,673
86,124,554	50,491,684	136,616,238	99,094,496
EXPENDITURE			
Clinical expenses 15 35,426,267		35,426,267	29,445,938
Administrative expenses 16 16,060,573	-	16,060,573	10,904,959
Finance cost 108,916	.	108,916	82,399
Expenses against zakat income (38,681,457)	38,681,457		
12,914,299	38,681,457	51,595,756	40,433,296
Taxation 3.17 -		•	
Total surplus for the year 73,210,255	11,810,227	85,020,482	58,661,200

The annexed notes from 1 to 22 form an integral part of these financial statements.

Dip

Plus)

CHIEF EXECUTIVE OFFICER

My

THE DIABETES CENTRE STATEMENT OF OTHER COMPREHENSIVE INCOME FOR THE YEAR ENDED JUNE 30, 2017

General fund	Restricted fund Rupe	2017 es	2016
73,210,255	11,810,227	85,020,482	58,661,200
•			•
73,210,255	11,810,227	85,020,482	58,661,200
	73,210,255	General fund fund Ruper 73,210,255 11,810,227	General fund fund 2017Rupees

The annexed notes from 1 to 22 form an integral part of these financial statements.

MA

Plus

CHIEF EXECUTIVE OFFICER

M

THE DIABETES CENTRE CASH FLOW STATEMENT FOR THE YEAR ENDED JUNE 30, 2017

	2017	2016 ees)
CASH FLOW FROM OPERATING ACTIVITIES	(Кар	ees)
Surplus for the year	85,020,482	58,661,200
Adjustments for:		
Depreciation on property and equipment	2,125,407	1,935,642
Amortization of intangibles	266,036	201,140
Provision against other receivables	232,002	152,062
	2,623,445	2,288,844
Changes in working capital:		
(Increase) / decrease in current assets		
Stock	244,922	(2,102,592)
Prepayments, accrued interest and other receivables	(630,005)	44,721
Investment		9,000,000
Increase / (Decrease) in current liabilities		
Trade and other payables	431,314	713,720
Cash generated from operations	46,231	7,655,849
Net cash generated from operating activities	87,690,158	68,605,893
CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property and equipment	(55,304,417)	(57,745,416)
Purchase of intangible asset		(629,999)
Net cash used in investing activities	(55,304,417)	(58,375,415)
Net increase in cash and cash equivalents	32,385,741	10,230,478
Cash and cash equivalents at the beginning of the year	17,715,261	7,484,783
Cash and cash equivalents at the end of the year	50,101,002	17,715,261

The annexed notes from 1 to 22 form an integral part of these financial statements.

DYN

CHIEF EXECUTIVE OFFICER

Mr

THE DIABETES CENTRE STATEMENT OF CHANGES IN FUNDS FOR THE YEAR ENDED JUNE 30, 2017

	Accumulated surplus fund	Restricted fund- Zakat Rupees	Total
Balance as at July 1, 2016	130,376,175	11,348,211	141,724,386
Surplus for the year	60,198,771	(1,537,571)	58,661,200
Balance as at June 30, 2016	190,574,946	9,810,640	200,385,586
Surplus for the year	73,210,255	11,810,227	85,020,482
Balance as at June 30, 2017	263,785,201	21,620,867	285,406,068

The annexed notes from 1 to 22 form an integral part of these financial statements.

MAD

(Plue)

CHIEF EXECUTIVE OFFICER

M

THE DIABETES CENTRE NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED JUNE 30, 2017

1. STATUS AND NATURE OF BUSINESS

- 1.1 The Diabetes Centre ("TDC" or "the Company") is a company limited by guarantee incorporated in Pakistan on December 7, 2011 under section 42 of the Companies Ordinance, 1984. The Company's registered office is located at Phulgran stop, near Toll Plaza, Muree Expressway, Islamabad.
- 1.2 The principal objective of the Company is to establish, support, run, manage and maintain hospitals, clinics, diagnostic center and indoor and out door treatment facilities all over Pakistan particularly for diabetes and generally for other diseases.

2. STATEMENT OF COMPLIANCE

These financial statements have been prepared in accordance with approved accounting standards as applicable in Pakistan. Approved accounting standards comprise of International Financial Reporting Standard for Small and Medium-sized Entities (IFRS for SMEs) issued by International Accounting Standards Board (IASB), Accounting Standards for Not for Profit Organisations (NPOs) and provisions of and directives issued under the Companies Ordinance, 1984. In case requirements differ, the provisions or directives of the Companies Ordinance, 1984 shall prevail.

During the year, the Companies Act, 2017 was enacted and promulgated by the Securities Exchange and Commission of Pakistan (SECP) on May 30, 2017. However, SECP has notified through circular No. 17 of July 20, 2017 that the companies whose financial year closes on or before June 30, 2017 shall prepare their financial statements in accordance with the provisions of the repealed Companies Ordinance, 1984.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3.1 Basis of preparation of financial statements

These financial statements have been prepared under the historical cost convention.

3.2 Property and equipment

Property and equipment except freehold land are stated at cost less accumulated depreciation and any identified impairment losses. Freehold land is stated at revalued amount less any identified impairment loss. Cost comprises acquisition and other directly attributable costs.

Depreciation on property and equipment is charged to income and expenditure account using reducing balance method so as to write-off the depreciable amount of the assets over their estimated useful life. Depreciation on additions to property and equipment is charged from the month in which the asset is available for use, while no depreciation is charged for the month in which the asset is disposed off.

3.3 Capital work in progress

Capital work in progress is stated at cost less any identified impairment loss. All expenditure connected with specific assets incurred during installation and construction period are carried under capital work in progress. These are transferred to property, plant and equipment as and when these are available for use.

3.4 Intangible assets

Expenditure incurred to acquire computer software is capitalized as intangible asset and stated at cost less accumulated amortization and any identified impairment loss. Computer software is amortized using straight line method over a period of three years.

3.5 Impairment of non-financial assets

Assets that have an infinite useful life - for example land - are not subject to depreciation/amortization and are tested annually for impairment. Assets that are subject to depreciation/amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset's carrying amount exceeds the recoverable amount. The recoverable amount is the higher of an asset's fair value less cost to sell and value in use.

3.6 Investments

Investments intended to be held for less than twelve months from the balance sheet date are included in current assets. All other investments are classified as non-current. Management determines the appropriate classification of the investments at the time of purchase and re-evaluates such designation on regular basis.

3.7 Financial assets

3.7.1 Classification

The Company classifies its financial assets in the following categories: at fair value through profit or loss, loans and receivables, available for sale and held to maturity. The classification depends on the purpose for which the financial assets were acquired. Management determines the classification of its financial assets at the time of initial recognition.

a) Financial assets through profit or loss

Financial assets at fair value through profit or loss are financial assets held for trading and financial assets designated upon initial recognition as at fair value through profit or loss. A financial asset is classified as held for trading if acquired principally for the purpose of selling in short term. Assets in this category is classified in current assets if expected to be settled within twelve months, otherwise they are classified in non-current assets.

b) Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in active market. They are included in current assets except where maturity is greater than twelve months after the balance sheet date, which are classified as non-current assets. Loans and receivables comprise, loans, advances, deposits and other receivables and cash and cash equivalent in the balance sheet.

c) Available-for-sale financial assets

Available-for-sale financial assets are non-derivative financial assets that are either designated in this category or not classified in any other categories. They are included in current assets unless management intends to dispose off the investments within twelve months from balance sheet date.

d) Held to maturity

These are financial assets with fixed or determinable payments, fixed maturity and the management intends to hold till maturity.

3.7.2 Recognition and measurement

All financial assets are recognized at the time when the Company becomes a party to contractual provision of the instrument. Regular purchases and sales of investments are recognized on trade date - the date on which the Company commits to purchase or sell the asset. Financial assets are carried at fair value through profit or loss. Financial assets carried at fair value through profit or loss are initially recognized at fair value and transaction costs are expensed in the income and expenditure account. Financial assets are derecognized when the rights to receive cash flow from assets have expired or have been transferred and the Company has transferred substantially all the risks and rewards of ownership. Available-for-sale financial assets are financial assets at fair value through profit or loss, which are subsequently carried at fair value. Loans and receivables and held-to-maturity investments are carried at amortized cost using effective interest rate method.

Gain or losses arising from changes in the fair value of the 'financial assets through profit or loss' category are presented in the income and expenditure account in the period in which they arise.

Changes in fair value of securities classified as available-for-sale are recognized in Other Comprehensive Income. When Available For Sale securities are sold or impaired, the accumulated fair value adjustments recognized in the fund are reclassified from the fund to income and expenditure account as reclassification adjustment. Interest on available-for-sale securities calculated using the effective interest method is recognized in income and expenditure account.

3.8 Financial liabilities

All financial liabilities are recognized at the time when the Company becomes a party to the contractual provisions of the instrument.

A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expired.

3.9 Offsetting of financial assets and financial liabilities

Financial assets and financial liabilities are offset and the net amount is reported in the financial statements only when there is a legally enforceable right to setoff the recognized amount and the Company intends either to settle on a net basis or to realize the assets and settle liabilities simultaneously.

3.10 Donation in kind

Assets received as donation are measured at the market value prevailing on the date when risks and rewards are transferred to the Company.

3.11 Stock

Stock is stated at lower of cost and net realizable value. Cost is determined on weighted average value basis. Net realizable value is determined with reference to estimated selling price less estimated expenditures to make the sale.

Amortization on additions in computer software is charged from the month in which the asset is available for use while no amortization is charged for the month in which the asset is disposed off.

3.12 Trade and other receivables

Trade debts and other receivables are stated at original invoice amount as reduced by appropriate provision for doubtful receivables based on review of outstanding amounts at the year end. Balances considered bad and irrecoverable are written off when identified.

3.13 Cash and cash equivalents

Cash and cash equivalents include cash in hand and deposits held at call with banks.

3.14 Income recognition

Income is recognized when it is probable that the economic benefits associated with the transaction will flow to the entity and the income can be measured reliably. Clinical income is recognized at the time when service is rendered. Zakat and donations are recognized when received. Return on deposits is accrued on time proportion basis by reference to the principal outstanding and the applicable rate of return. Properties and other items received as donation in kind are recorded at market value at the time of receipt of donations.

3.15 Foreign currency

Transaction in foreign currency during the year are translated in to PKR at the rate of exchange prevailing at the date of transaction. All monetary assets and liabilities are translated into PKR at the rate of exchange prevailing at the balance sheet date and the difference is recognized in income and expenditure account.

3.16 Restricted fund

This restricted fund is utilized for the treatment of patients who are eligible for zakat.

3.17 Taxation

As per provisions of section 100C of Income Tax Ordinance, 2001, the Company is allowed a tax credit equal to 100% of the tax payable upon filing of annual tax return as per section 118(2)(a) read with Rule 217(1)(b)(vi) of the Income Tax Rules 2002.

4	4. PROPERTY AND EQUIPMENT	Note	2017 (Rupe	2016 es)			
	Operating fixed assets Capital work in progress	t.4 6.	52,683,235 167,231,587 219,914,822	44,406,002 116,204,810 160,610,812			

Operating fixed assets 4.1

Description	Land	Clinic building	Furnitures and fixtures	Computer equipment	Office equipment Lab equipment	Lab equipment	Medical equipment	Vehicles	Total
					(Rupees)	(Rupees)			-
Cost									
As at July 1, 2015	26,375,000	6,227,705	390,087	885,116	3,242,334	1,570,000	2,545,000	3,497,172	44,732,414
Additions		1,831,735	107,000	234,333	1,171,381		256,800		3,601,249
Disposal				•					
As at June 30, 2016	26,375,000	8,059,440	497,087	1,119,449	4,413,715	1,570,000	2,801,800	3,497,172	48,333,663
As at 1.1V 1 2016	26 375 000	8 059 440	497.087	1,119,449	4.413.715	1,570,000	2,801,800	3,497,172	48,333,663
Additions	-		414,403	235,924	505,653	29,107	2,250,327	842,226	4,277,640
Disposal				•	•		•		
Revaluation	6,125,000		•						6,125,000
As at June 30, 2017	32,500,000	8,059,440	911,490	1,355,373	4,919,368	1,599,107	5,052,127	4,339,398	58,736,303
Accumulated depreciation									
200 tillion 2004		426 738	51 329	291 061	404 397	189 975	127,625	500.894	1.992.019
Charge for the year		381,635	42,433	212,566	308,831	138,003	252,918	599,256	1,935,642
Depreciation on disposal									
As at June 30, 2016		808,373	93,762	503,627	713,228	327,978	380,543	1,100,150	3,927,661
As at Iniv 1 2016		808.373	93,762	503,627	713,228	327,978	380,543	1,100,150	3,927,661
Charge for the year		362,556	45,552	208,212	395,817	124,614	402,871	585,785	2,125,407
Depreciation on disposal									
As at June 30, 2017		1,170,929	139,314	711,839	1,109,045	452,592	783,414	1,685,935	6,053,068
Carrying amount as at June 30, 2016	26,375,000	7,251,067	403,325	615,822	3,700,487	1,242,022	2,421,257	2,397,022	44,406,002
Carrying amount as at June 30, 2017	32,500,000	6,888,511	772,176	643,534	3,810,323	1,146,515	4,268,713	2,653,463	52,683,235
Rate of depreciation per annum %		5	10	33	10	10	10	20	

4.1.1 Revaluation of land

The Company's freehold land is carried at the fair value at the date of revaluation, less any subsequent accumulated impairment losses. The fair value measurements of the Company's land as at November 16, 2016 were performed by M/S DIMENSIONS, independent valuers not related to the Company. M/S DIMENSIONS are on list of approved valuers issued by Pakistan Banks Association. They have the appropriate qualifications and experience in fair value measurement in the relevant locations.

1.2		follows:	2047	2016
		Note	2017 (Rupe	2016 es)
			507.405	200.024
	Clinical expenses	15 16	527,485 1,597,922	390,921 1,544,721
	Administrative expenses	10 _	2,125,407	1,935,642
.3	Capital work in progress			
			116,204,810	62,060,643
	Opening balance Additions during the year		51,026,777	54,144,167
			167,231,587	116,204,810
1.3.1	Cost of construction			
	On the halaman		104,482,310	62,060,643
	Opening balance Additions during the year		41,874,616	42,421,667
	Additions during the year		146,356,926	104,482,310
4.3.2	Advances for construction work	-		
	Opening balance		11,722,500	
	Additions during the year		9,152,161	11,722,500
		4.3.2.1	20,874,661	11,722,500
4.3.2.1	These advances include amounts paid to suppliers for	the construction of building.		
				2010
			2017	2016
		Note		2016 ees)
5.	INTANGIBLE ASSETS	Note		
5.	INTANGIBLE ASSETS Opening balance	Note		136,081
5.	Opening balance Additions during the year		(Rupe 564,940 -	136,081 629,999
5.	Opening balance Additions during the year Less: Amortization for the year	Note	564,940 - (266,036)	136,081 629,999 (201,140
5.	Opening balance Additions during the year		(Rupe 564,940 -	136,081 629,999 (201,140
5. 5.1	Opening balance Additions during the year Less: Amortization for the year	5.1 <u> </u>	564,940 - (266,036)	136,081 629,999 (201,140
	Opening balance Additions during the year Less: Amortization for the year Closing balance Amortization charge for the year has been allocated as	5.1 <u> </u>	564,940 - (266,036)	136,081 629,999 (201,140 564,940
	Opening balance Additions during the year Less: Amortization for the year Closing balance	5.1 _ = s follows:	564,940 - (266,036) 298,904	136,081 629,999 (201,140 564,940
	Opening balance Additions during the year Less: Amortization for the year Closing balance Amortization charge for the year has been allocated as Clinical expenses	5.1 _ = s follows:	564,940 - (266,036) 298,904	136,081 629,999 (201,140 564,940 168,773 32,367
	Opening balance Additions during the year Less: Amortization for the year Closing balance Amortization charge for the year has been allocated as Clinical expenses	5.1 _ = s follows:	(Rupe 564,940 - (266,036) 298,904 = 223,226 42,810	136,081 629,999 (201,140 564,940 168,773 32,367
5.1	Opening balance Additions during the year Less: Amortization for the year Closing balance Amortization charge for the year has been allocated as Clinical expenses Administrative expenses	5.1 _ = s follows: 15 16 _ =	223,226 42,810 266,036	136,081 629,999 (201,140 564,940 168,773 32,367
5.1	Opening balance Additions during the year Less: Amortization for the year Closing balance Amortization charge for the year has been allocated as Clinical expenses Administrative expenses	5.1 es follows: 15 16 ems carried at weighted ave	223,226 42,810 266,036 298,904 223,226 42,810 266,036	136,081 629,999 (201,140 564,940 168,773 32,367 201,140
5.1	Opening balance Additions during the year Less: Amortization for the year Closing balance Amortization charge for the year has been allocated as Clinical expenses Administrative expenses	5.1 _ = s follows: 15 16 _ =	223,226 42,810 266,036 298,904	136,081 629,999 (201,140 564,940 168,773 32,367 201,140
5.1 6.	Opening balance Additions during the year Less: Amortization for the year Closing balance Amortization charge for the year has been allocated as Clinical expenses Administrative expenses	5.1 es follows: 15 16 ems carried at weighted ave	223,226 42,810 266,036 298,904 223,226 42,810 266,036	136,081 629,999 (201,140 564,940 168,773 32,367 201,140
5.1 6.	Opening balance Additions during the year Less: Amortization for the year Closing balance Amortization charge for the year has been allocated as Clinical expenses Administrative expenses STOCK This represents medicines and medical consumable ite PREPAYMENTS, ACCRUED INTEREST	5.1 s follows: 15 16 ems carried at weighted ave	223,226 42,810 266,036 298,904 223,226 42,810 266,036 rage value.	136,081 629,999 (201,140 564,940 168,773 32,367 201,140
5.1 6.	Opening balance Additions during the year Less: Amortization for the year Closing balance Amortization charge for the year has been allocated as Clinical expenses Administrative expenses STOCK This represents medicines and medical consumable ite PREPAYMENTS, ACCRUED INTEREST AND OTHER RECEIVABLES	5.1 es follows: 15 16 ems carried at weighted ave	266,036) 298,904 223,226 42,810 266,036 rage value. 2017 71,451 469,884	136,081 629,999 (201,140 564,940 168,773 32,367 201,140 2016 ees)
5.1 6.	Opening balance Additions during the year Less: Amortization for the year Closing balance Amortization charge for the year has been allocated as Clinical expenses Administrative expenses STOCK This represents medicines and medical consumable its PREPAYMENTS, ACCRUED INTEREST AND OTHER RECEIVABLES Prepaid vehicle insurance	5.1 s follows: 15 16 ems carried at weighted ave	564,940 (266,036) 298,904 223,226 42,810 266,036 rage value. 2017 71,451 469,884 848,297	136,081 629,999 (201,140 564,940 168,773 32,367 201,140 2016 ees)
5.1 6.	Opening balance Additions during the year Less: Amortization for the year Closing balance Amortization charge for the year has been allocated as Clinical expenses Administrative expenses STOCK This represents medicines and medical consumable ite PREPAYMENTS, ACCRUED INTEREST AND OTHER RECEIVABLES Prepaid vehicle insurance Accrued interest Other receivables - Considered doubtful	5.1	71,451 469,884 848,297 1,389,632	136,081 629,999 (201,140 564,940 168,773 32,367 201,140 2016 ees)
5.1	Opening balance Additions during the year Less: Amortization for the year Closing balance Amortization charge for the year has been allocated as Clinical expenses Administrative expenses STOCK This represents medicines and medical consumable its PREPAYMENTS, ACCRUED INTEREST AND OTHER RECEIVABLES Prepaid vehicle insurance Accrued interest	5.1 s follows: 15 16 ems carried at weighted ave	564,940 (266,036) 298,904 223,226 42,810 266,036 rage value. 2017 71,451 469,884 848,297	136,081 629,999 (201,140 564,940 168,773 32,367 201,140

		2017	2016
7.2	Provision for doubtful - other receivable	(Rupee	:s)
	Opening balance Provision for the year	616,295 232,002	464,233 152,062
	Closing balance	848,297	616,295
8.	INVESTMENT		
	Investment has been made in TDRs carrying markup ranging from 4.48 p.a).	% p.a to 4.88% p.a (2016: 2.65	5% p.a to 4.19%
		2017	2016

		2017	2016
		(Rupe	es)
9.	CASH AND BANK BALANCES		
	Cash in hand	554,140	732,811
	Cash at bank - local currency		
	-deposit account	17,094,750	5,740,953
	-current account	31,966,397	7,959,194
	Cash at bank - foreign currency		
	-current account	485,715	3,282,303
		50,101,002	17,715,261

9.1 Deposit account carries effective markup ranging from 2.12% to 2.40% (2016: 1.65% - 2.38%) per annum.

		2017	2016
		(Rupe	es)
10.	TRADE AND OTHER PAYABLES		
	Creditors	127,792	268,333
	Salaries payable	182,366	324,180
	Auditors' remuneration payable	70,000	50,000
	Accrued liabilities	734,346	101,843
	Withholding tax payable	268,161	206,995
		1,382,665	951,351

11. CONTINGENCIES AND COMMITMENTS

11.1 Contingencies

(i) The tax department is in process of finalizing audit of the Company for the tax year 2013. Further, notice under section 161 (1A) of Income Tax Ordinance, 2001 for the tax year 2016 has been received by the Company during the year, giving an opportunity to the Company to explain the position for non deduction of withholding tax amounting to Rs. 1,937,460.

The management of the Company and tax advisors are of the opinion that the Company has strong cases. Hence, no provision has been recorded in these financial statements.

11.2 Commitments

No commitment exists as at June 30, 2017 (2016: Nil).

			2017	2016
		Note	(Rupe	es)
12.	CLINICAL INCOME	12.1	22,487,989	12,609,908

12.1 This represents income earned in respect of fees charged to patients.

			2017	2016
		_	(Rupe	es)
13.	DONATIONS			
	Donations	13.1	112,250,492	83,145,153
	Membership fee	13.2 _	691,200	2,186,762
			112,941,692	85,331,915

- Donations include amount received on account of zakat of Rs. 50,434,484 (2016: Rs. 23,610,723) and donations in kind amounting to Rs. 2,068,487 (2016: Rs. 200,000).
- 13.2 TDC's membership is awarded on the basis of following criteria:
 - a) Founding members against a one time non-refundable deposit of AED 100,000 or equivalent US\$ for overseas members and Rs. 2,500,000 for Pakistani members. They will be eligible for free medical treatment including spouse. However, this excludes major heart or other surgery.
 - b) Members against a one time non-refundable deposit of AED 10,000 or equivalent US\$ for overseas members and Rs. 250,000 for Pakistani members. They become eligible for free consultation from the hospital.
 - c) Voluntary membership Free of cost and on commitment of providing personal services for TDC's development.

		Note	2017 (Ru	2016
14.	OTHER INCOME	Note	(Nu	pees)
	Income from financial assets			
	Interest on deposits and investment		1,176,173	1,102,951
	Exchange gain		10,384	49,722
			1,186,557	1,152,673
15.	CLINICAL EXPENSES			
	Salaries of doctors and paramedical staff		10,953,585	7,359,289
	Medical supplies and consumables		23,721,971	21,526,955
	Depreciation	4.2	527,485	390,921
	Amortization	5.1	223,226	168,773
	Amortization		35,426,267	29,445,938
16.	ADMINISTRATIVE EXPENSES			
	Salaries of administrative staff		5,599,928	4,128,112
	Staff training and education expenses		65,000	•
	Zakat management system fee		452,794	302,975
	Utilities		902,245	317,603
	Security expenses		668,160	420,930
	Marketing expenses		3,563,699	1,217,431 478,861
	Printing and stationery		396,950 151,030	30,750
	Professional fees and charges Auditors' remuneration		70,000	50,000
	Entertainment		305,144	295,978
	Communication		187,091	178,645
	Travelling and conveyance		153,300	190,020
	Repair and maintenance		524,654	458,022
	Vehicle running and maintenance		673,507	652,692
	Fuel for generator		170,068	238,552
	Insurance expense		36,100	57,491
	Depreciation	4.2	1,597,922	1,544,721
	Provision against other receivables		232,002	152,062
	Amortization	5.1	42,810	32,367
	Miscellaneous expenses		268,169	157,747
			16,060,573	10,904,959

Received during the year 13.1 50,491,684 23,610 Payments made: Staff salaries and wages Medical supplies and consumables Other clinical expenses Amount utilized under free treatment of zakat patients 39,681,457 25,148 21,820,867 9,810 17.1 This fund is utilized for the treatment of patients who are eligible for zakat. 18. TRANSACTIONS WITH RELATED PARTIES The related parties include Chief Executive and Directors. No remuneration or any other benefits were paid to their the Company during the period. Detail of transactions with related parties are as follows: 2017 2016 Nature Donations received by the Company from the Directors 10,729,094 9,845,000 Financial instruments by category 2017 2016 (Rupees) Financial assets as per balance sheet Loans and receivables Accrued interest 489,884 143; Investment 20,000,000 20,000,000 20,000,000 20,000,00				2017	2016
Received during the year 13.1 50,491,684 23,610 Payments made: Staff salaries and wages Medical supplies and consumables Other clinical expenses Amount utilized under free treatment of zakat patients 39,681,457 25,148 21,820,867 9,810 17.1 This fund is utilized for the treatment of patients who are eligible for zakat. 18. TRANSACTIONS WITH RELATED PARTIES The related parties include Chief Executive and Directors. No remuneration or any other benefits were paid to their the Company during the period. Detail of transactions with related parties are as follows: 2017 2016 (Rupees) Nature Donations received by the Company from the Directors 10,729,094 9,845,0 19. FINANCIAL INSTRUMENTS 19.1 Financial instruments by category 2017 2016 (Rupees) Accrued interest 489,884 143; Investment 20,000,000 20,000,000 20,000,000 20,000,00	17.	RESTRICTED FUND - ZAKAT	Note	(Rupe	es)
Payments made: Staff salaries and wages Medical supplies and consumables Other clinical expenses Amount utilized under free treatment of zakat patients Amount utilized under free treatment of zakat patients 38,681,457 25,148 21,620,867 9,810 17.1 This fund is utilized for the treatment of patients who are eligible for zakat. 18. TRANSACTIONS WITH RELATED PARTIES The related parties include Chief Executive and Directors. No remuneration or any other benefits were paid to their the Company during the period. Detail of transactions with related parties are as follows: 2017 2016 (Rupees)		Opening balance		9,810,640	11,348,211
Staff salaries and wages Medical supplies and consumables 15,376 15,376 596 15,376 596 16,376		Received during the year	13.1	50,491,684	23,610,723
15,376 596 596		Payments made:			
15,376 596 596		Staff salaries and wages			9,175,647
Amount utilized under free treatment of zakat patients 38,681,457 38,681,457 25,148 21,620,867 9,810 17.1 This fund is utilized for the treatment of patients who are eligible for zakat. 18. TRANSACTIONS WITH RELATED PARTIES		Medical supplies and consumables			15,376,116
17.1 This fund is utilized for the treatment of patients who are eligible for zakat. 18. TRANSACTIONS WITH RELATED PARTIES The related parties include Chief Executive and Directors. No remuneration or any other benefits were paid to their the Company during the period. Detail of transactions with related parties are as follows: 2017				-	596,531
17.1 This fund is utilized for the treatment of patients who are eligible for zakat. 18. TRANSACTIONS WITH RELATED PARTIES The related parties include Chief Executive and Directors. No remuneration or any other benefits were paid to their the Company during the period. Detail of transactions with related parties are as follows: 2017		Amount utilized under free treatment of zakat patients			
17.1 This fund is utilized for the treatment of patients who are eligible for zakat. 18. TRANSACTIONS WITH RELATED PARTIES The related parties include Chief Executive and Directors. No remuneration or any other benefits were paid to there the Company during the period. Detail of transactions with related parties are as follows: 2017 2016 (Rupees) Nature Donations received by the Company from the Directors 10,729,094 9,845,6 19. FINANCIAL INSTRUMENTS 19.1 Financial instruments by category 2017 2016 (Rupees) Financial assets as per balance sheet Loans and receivables Accrued interest 469,884 143,6 Investment 20,000,000 20,000,000 20,000,000 20,000,00				38,681,457	25,148,294
The related parties include Chief Executive and Directors. No remuneration or any other benefits were paid to their the Company during the period. Detail of transactions with related parties are as follows: 2017				21,620,867	9,810,640
The related parties include Chief Executive and Directors. No remuneration or any other benefits were paid to their the Company during the period. Detail of transactions with related parties are as follows: 2017	17.1	This fund is utilized for the treatment of patients who are	eligible for zakat.		
the Company during the period. Detail of transactions with related parties are as follows: 2017 2016 (Rupees) Nature Donations received by the Company from the Directors 10,729,094 9,845,1 19. FINANCIAL INSTRUMENTS 19.1 Financial instruments by category 2017 2016 (Rupees) Financial assets as per balance sheet Loans and receivables Accrued interest 469,884 143,1 Investment 20,000,000 20,000,000 Cash and bank balances 50,101,002 17,715,6 70,570,886 37,856,5 Financial liabilities as per balance sheet Amortized cost Trade and other payables 1,114,504 744,5	18.	TRANSACTIONS WITH RELATED PARTIES			
Nature CRupees Nature Nature Donations received by the Company from the Directors 10,729,094 9,845,0					e paid to them by
Nature Donations received by the Company from the Directors 10,729,094 9,845,000					
19. FINANCIAL INSTRUMENTS 19.1 Financial instruments by category 2017 2016 (Rupees) Financial assets as per balance sheet Loans and receivables Accrued interest 469,884 143,3 Investment 20,000,000 20,000,0 Cash and bank balances 50,101,002 17,715,3 70,570,886 37,858,5 Financial liabilities as per balance sheet Amortized cost Trade and other payables 1,114,504 744,5		Nature		(Rupe	es)
2017 2016 (Rupees) (Rupees) (Rupees) (Rupees) (Rupees) (Rupees) (Rupees) (Rupees) (Rupees) (Rupees) (Ru		Donations received by the Company from the Directors		10,729,094	9,845,023
2017 2016	19.	FINANCIAL INSTRUMENTS			
Financial assets as per balance sheet Loans and receivables Accrued interest	19.1	Financial instruments by category			
Financial assets as per balance sheet Loans and receivables 469,884 143,3 Accrued interest 20,000,000 20,000,0 Investment 20,000,000 20,000,0 Cash and bank balances 50,101,002 17,715,2 70,570,886 37,858,5 Financial liabilities as per balance sheet Amortized cost Trade and other payables 1,114,504 744,5				2017	2016
Loans and receivables Accrued interest 469,884 143,3 Investment 20,000,000 20,000,0 Cash and bank balances 50,101,002 17,715,7 70,570,886 37,858,8 Financial liabilities as per balance sheet Amortized cost Trade and other payables 1,114,504 744,3				(Rupee	s)
Investment					
Investment		Accrued interest		469,884	143,332
Financial liabilities as per balance sheet Amortized cost Trade and other payables 70,570,886 37,858,9 1,114,504 744,7		Investment		20,000,000	20,000,000
Financial liabilities as per balance sheet Amortized cost Trade and other payables 744,		Cash and bank balances		50,101,002	17,715,261
Amortized cost Trade and other payables				70,570,886	37,858,593
Amortized cost Trade and other payables		Financial liabilities as per balance sheet			
		Trade and other payables		1,114.504	744,356
					744,356

20. NUMBER OF EMPLOYEES

Total and average number of employees of the Company were as follows:

	2017	2016
	(No of en	nployees)
Total employees at reporting date	46	31
Average employees during the year	36	23

21. DATE OF AUTHORIZATION FOR ISSUE

22. GENERAL

Figures have been rounded off to the nearest Rupee.

DYK

CHIEF EXECUTIVE OFFICER